20579-43-5

Basic information

• Product Name: 3,4,5-trimethylpyridine
• Synonyms: 3,4,5-trimethylpyridine;Einecs 243-893-4
• CAS NO: 20579-43-5
• Molecular Formula: C₈H₁₁N
• Molecular Weight: 121.17964
• EINECS: 243-893-4
• Mol File: 20579-43-5.mol

Chemical Properties

• Melting Point: 32.6-35.6 °C
• Boiling Point: 211.6°Cat760mmHg
• Flash Point: 71.2°C
• Appearance: /
• Density: 0.921g/cm³
• Vapor Pressure: 0.262mmHg at 25°C
• Refractive Index: 1.502
• PKA: 6.47±0.28(Predicted)
• CAS DataBase Reference: 3,4,5-trimethylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4,5-trimethylpyridine(20579-43-5)
• EPA Substance Registry System: 3,4,5-trimethylpyridine(20579-43-5)

Safety Data

• Hazardous Substances Data: 20579-43-5(Hazardous Substances Data)

Usage

Physical Form

Powder

Uses

3,4,5-trimethylpyridine is a useful research chemical.

InChI:InChI=1/C8H11N/c1-6-4-9-5-7(2)8(6)3/h4-5H,1-3H3

Upstream product

• 98490-98-3 2,6-dichloro-3,4,5-trimethyl-pyridine 
• 102471-57-8 1-benzyl-3,4,5-trimethyl-piperidin-4-ol 
• 3430-23-7 3,5-dibromo-4-methyl-pyridine 
• 594-27-4 tetramethylstannane 
• 625-92-3 3,5-dibromopyridine 
• 836-21-5 1-Benzyl-3,5-dimethyl-piperidin-4-one 
• 42324-07-2 2,4-dimethyl-3-oxo-pentanedioic acid diethyl ester 
• 110331-19-6 1-benzyl-3,5-dimethyl-4-oxo-piperidine-3,5-dicarboxylic acid diethyl ester 
• 98593-42-1 trimethyl-pyridine-2,6-diol 
• 497-03-0 2-methylbut-2-enal 
• 2450-71-7 Propargylamine 

Downstream Products

• 524775-16-4 4-(2-(3,4-bis-difluoromethoxy-phenyl)-2-{4-[2,2,2-trifluoro-1-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethoxy)-ethyl]-phenyl}-ethyl)-3,5-dimethyl-pyridine 

Relevant articles and documents

NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS

The present invention relates to novel methods of preparation of substituted pyridines and the compounds produced therefrom. In particular, the present invention provides efficient methods for the construction of diversely substituted pyridines, with varying substitution patterns under simple and metal-free conditions with high atom- and pot-economy and excellent functional group tolerance, and which are useful for the synthesis of natural products.

A simple, tandem approach to the construction of pyridine derivatives under metal-free conditions: A one-step synthesis of the monoterpene natural product, (-)-actinidine

A simple and modular one-step synthesis of diversely substituted pyridines from readily available α,β-unsaturated carbonyl compounds and propargylic amines has been developed. The present protocol has a broad substrate scope and allows access to multi-substituted pyridines with select control of the substitution pattern under mild and metal-free conditions. The reaction involves imine formation followed by concomitant cyclization through an allenyl intermediate to afford pyridines in excellent yields, with water as the sole by-product. This mild strategy is also suitable for functionalization of natural products or other advanced intermediates having α,β-unsaturated carbonyl functionality. The utility of the present protocol was showcased with the synthesis of the monoterpene alkaloid, (-)-actinidine, an ant-associated iridoid.

Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction

The invention concerns inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction, characterized by formula I wherein, X, Y and Z independently represent C or N; ------ is an optional double bond; n is 0 or 1; R1, R2, and R4 independently represent hydrogen, a chemical bond, C1-10 alkyl; C2-10 alkenyl; C2-10 alkinyl; aryl; aryl-C1-10 alkyl; C3-10 heterocyclyl; C5-10 heteroaryl; halo, CF3; NO2; NHC(O)R*, OR, said alkyl, alkenyl, alkinyl, aryl, arylalkyl, heterocyclyl, or heteroaryl being optionally substituted; R3, R5, and R6 independently represent hydrogen, C1-10alkyl; C2-10 alkenyl; C2-10 alkinyl; aryl; aryl-C1-10alkyl; C3-10 heterocyclyl; C5-10 heteroaryl; halo, CF3; NO2; NHC(O)R*, OR, said alkyl, alkenyl, alkinyl, aryl, heterocyclyl, or heteroaryl being optionally substituted; or R5 and R6 together form a 5- or 6-member aryl, heterocyclyl or heteroaryl group; R is hydrogen or C1-6 alkyl; R* is hydrogen, or C1-6 alkyl, or OH, wherein the optional substituents are preferably selected from the group of one to three OH, C1-6 alkyl, halo, NO2, C1-6 alkoxy, and CF3, or a pharmaceutically acceptable salt thereof.

Substituted 4-(2,2-Diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters

A detailed SAR study directed toward the optimization of pharmacokinetic parameters for analogues of L-791,943 is reported. The introduction of a soft metabolic site on this structure permitted the identification of L-826,141 as a potent phosphodiesterase type 4 (PDE4) inhibitor that is well absorbed and that presents a shorter half-life than L-791,943 in a variety of animal species. The efficacy of L-826,141 is also demonstrated in different in vivo models.